Based on the Oncternal Therapeutics Inc stock forecast from 0 analysts, the average analyst target price for Oncternal Therapeutics Inc is not available over the next 12 months. Oncternal Therapeutics Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Oncternal Therapeutics Inc is Slightly Bearish, which is based on 3 positive signals and 4 negative signals. At the last closing, Oncternal Therapeutics Inc’s stock price was USD 0.53. Oncternal Therapeutics Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and -93.95% over the last year.
No recent analyst target price found for Oncternal Therapeutics Inc
No recent average analyst rating found for Oncternal Therapeutics Inc
Company Overview Oncternal Therapeutics Inc
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The company has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. is headquartered in San Diego, California. Read Less
Oncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-...Read More
Frequently Asked Questions About Oncternal Therapeutics Inc (ONCT) Stock
Stock Target Advisor's fundamental analysis for Oncternal Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ONCT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ONCT's stock to indicate what its average analyst target is.
ONCT stock's Price/Earning ratio is 2.11.
Our analysis grades ONCT stock's Price / Earning ratio at D. This means that ONCT stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ONCT may be fairly valued for its sector
The last closing price of ONCT's stock was USD 0.53.
The most recent market capitalization for ONCT is USD 1.56M.
Unfortunately we do not have enough analyst data on ONCT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Oncternal Therapeutics Inc's stock.
As per our most recent records Oncternal Therapeutics Inc has 27 Employees.
Oncternal Therapeutics Inc's registered address is 12230 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Oncternal Therapeutics Inc's website at https://www.oncternal.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Oncternal Therapeutics Inc (ONCT) Stock
Stock Target Advisor's fundamental analysis for Oncternal Therapeutics Inc's stock is Slightly Bearish.
Unfortunately we do not have enough data on ONCT's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on ONCT's stock to indicate what its average analyst target is.
ONCT stock's Price/Earning ratio is 2.11.
Our analysis grades ONCT stock's Price / Earning ratio at D. This means that ONCT stock's Price/Earning ratio is above 37% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ONCT may be fairly valued for its sector
The last closing price of ONCT's stock was USD 0.53.
The most recent market capitalization for ONCT is USD 1.56M.
Unfortunately we do not have enough analyst data on ONCT's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Oncternal Therapeutics Inc's stock.
As per our most recent records Oncternal Therapeutics Inc has 27 Employees.
Oncternal Therapeutics Inc's registered address is 12230 El Camino Real, San Diego, CA, United States, 92130.
You can get more information about it from Oncternal Therapeutics Inc's website at https://www.oncternal.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ONCT !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
